Trasplante de microbiota fecal: revisión de la literatura y reporte del primer caso en el Hospital Central Militar
Contenido principal del artículo
Resumen
Mujer en la novena década de la vida con hospitalización reciente por fractura de cadera. Acudió al servicio de urgencias por evacuaciones diarreicas y deshidratación moderada. Se le diagnosticó colitis pseudomembranosa por C. difficile y se inició tratamiento antibiótico con metronidazol y vancomicina sin mejoría a las 72 horas de hospitalización. Se le propuso efectuar trasplante de microbiota fecal que se realizó de manera exitosa en cinco sesiones en concomitancia con el tratamiento antibiótico, con curación de la enfermedad.
Detalles del artículo
Sección
Cómo citar
Referencias
Koenigsknecht MJ and Young VB. Fecal microbial transplantation for the treatment of Clostridium difficile infection: current promise and future needs. Curr Opin Gastroenterol 2013;29(6):628–32.
Pacheco SM, Johnson S. Important clinical advances in the understanding of Clostridium difficile infection. Curr Opin Gastroenterol 2013;29(1):42–8.
Ghantoji SS, Sail K, Lairson DR, Dupont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010;74(4):309–18.
O’Keefe SJ. Tube feeding, the microbiota, and Clostridium difficile infection. World J Gastroenterol 2010;16(2):139.
Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O’Connor L, et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013;369(13):1195–205.
Suárez MDA. Colitis pseudomembranosa: ¿nuevas toxinas? Rev Gastroenterol Mex 2010;1(75):120–3.
Kelly CP, LaMont JT. Clostridium difficile — more difficult than ever. N Engl J Med 2008;359(18):1932-40.
Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31.
Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe,
Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-9.
McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20: 43-50.
Fekety R, McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324-33.
Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin N Am 2012;41(4):781-803.
Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010;44(5):354–60.
Vos WM De. Fame and future of faecal transplantations – developing next-generation therapies with synthetic microbiomes. Microb Biotechnol 2013;6(4):316-25.
Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365(18):1693-703.
Anderson JL, Edney RJ, Whelan K. Alimentary pharmacology and therapeutics systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol 2012; 36(6):503-16.
Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc 2012;87(11):1106–17.
Song Y, Garg S, Girotra M. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One 2013;8(11):e81330.
Abbeele P Van Den, Verstraete W, El S, Geirnaert A, Wiele T Van De. Prebiotics, faecal transplants and microbial network units to stimulate biodiversity of the human gut microbiome. Microb Biotechnol 2013;6(4):335-40.
Brandt LJ, Borody TJ. Endoscopic fecal microbiota transplantation. J Clin Gastroenterol 2011;45(8):655–7.
Minero-Alfaro JI, Villatoro-Villar M, Martínez-López H, Magaña-García A, Guerrero-Guerrero VH, Ordaz-García A, et al. Experiencia en trasplante de microbiota fecal en el Hospital Central Militar. Rev Gastroenterol Mex 2014;79(Supl 2):2, ID 130.
Johan S. Bakken TB. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9(12):1044–9.
Agito MD, Atreja A, Rizk MK. Fecal microbiota transplantation for recurrent C difficile infection: Ready for prime time? Cleve Clin J Med 2013;80(2):101-8.